Northern Financial Advisors Inc Buys 592 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Northern Financial Advisors Inc raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,008 shares of the biopharmaceutical company’s stock after buying an additional 592 shares during the quarter. Northern Financial Advisors Inc’s holdings in Gilead Sciences were worth $325,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in GILD. Nilsine Partners LLC grew its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. boosted its holdings in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares during the period. Financial Counselors Inc. increased its stake in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Revolve Wealth Partners LLC boosted its stake in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 130 shares during the period. Finally, Institutional & Family Asset Management LLC increased its stake in Gilead Sciences by 10.3% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 140 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GILD shares. Maxim Group reduced their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. UBS Group reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research note on Wednesday, April 24th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Morgan Stanley reduced their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Trading Down 0.6 %

Shares of NASDAQ GILD traded down $0.40 during trading on Wednesday, hitting $65.06. 1,893,236 shares of the company were exchanged, compared to its average volume of 7,390,684. Gilead Sciences, Inc. has a 12-month low of $64.33 and a 12-month high of $87.86. The firm has a market capitalization of $81.00 billion, a PE ratio of 181.83, a P/E/G ratio of 1.31 and a beta of 0.22. The company has a fifty day moving average price of $70.25 and a 200-day moving average price of $75.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.37 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.73%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.